NKGen Biotech Korea corrects 2023 sales to KRW 9.95 billion from KRW 10.77 billion
NKGN•NKGen Biotech Korea corrected its 2025 annual report on November 18, 2026, revising 2023 sales to KRW 9.95 billion from KRW 10.77 billion. Recombinant protein export sales were revised to KRW 2.48 billion from KRW 3.3 billion.
1. Revised sales figures
NKGen Biotech Korea corrected its 2025 annual report, reducing reported 2023 sales to KRW 9.95 billion from KRW 10.77 billion due to a reporting error. Recombinant protein export sales were revised to KRW 2.48 billion from KRW 3.3 billion, and historical sales previously classified as cell therapies were reassigned to NK Vue Kit for 2024 and 2023.




